{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:39:13Z","timestamp":1792787953294,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T00:00:00Z","timestamp":1752796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T00:00:00Z","timestamp":1752796800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Shenzhen Science and Technology Program","award":["JCYJ20240813150249044"],"award-info":[{"award-number":["JCYJ20240813150249044"]}]},{"name":"Shenzhen Science and Technology Program","award":["JCYJ20240813150301003"],"award-info":[{"award-number":["JCYJ20240813150301003"]}]},{"name":"Shenzhen Science and Technology Program","award":["JCYJ20240813150419026"],"award-info":[{"award-number":["JCYJ20240813150419026"]}]},{"name":"Research Start-up Fund of Post-doctoral of SAHSYSU","award":["ZSQYRSFPD0079"],"award-info":[{"award-number":["ZSQYRSFPD0079"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32400649"],"award-info":[{"award-number":["32400649"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272689"],"award-info":[{"award-number":["82272689"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2023A1515110507"],"award-info":[{"award-number":["2023A1515110507"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2023M744019"],"award-info":[{"award-number":["2023M744019"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shenzhen Medical Research Fund","award":["D2301013"],"award-info":[{"award-number":["D2301013"]}]},{"name":"Sun Yat-sen University 100 Talents Plan\u2019s introduction of start-up funds","award":["ZSQYBRJH0022"],"award-info":[{"award-number":["ZSQYBRJH0022"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"DOI":"10.1186\/s12951-025-03607-4","type":"journal-article","created":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T02:39:04Z","timestamp":1752806344000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Enhancing the potency of 5T4 mRNA vaccine by CD70 mRNA-LNPs through ADCC and T cell boosting in prostate cancer therapy"],"prefix":"10.1186","volume":"23","author":[{"given":"Fei","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuandong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yupeng","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kexin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haowei","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunru","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ze Xiu","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gao-feng","family":"Zha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,18]]},"reference":[{"key":"3607_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74:12\u201349. https:\/\/doi.org\/10.3322\/caac.21820.","journal-title":"CA Cancer J Clin"},{"key":"3607_CR2","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1016\/S0140-6736(24)00651-2","volume":"403","author":"ND James","year":"2024","unstructured":"James ND, Tannock I, N\u2019Dow J, Feng F, Gillessen S, Ali SA, Trujillo B, Al-Lazikani B, Attard G, Bray F, et al. The lancet commission on prostate cancer: planning for the surge in cases. Lancet. 2024;403:1683\u2013722. https:\/\/doi.org\/10.1016\/S0140-6736(24)00651-2.","journal-title":"Lancet"},{"key":"3607_CR3","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.eururo.2011.04.038","volume":"60","author":"H Beltran","year":"2011","unstructured":"Beltran H, Beer TM, Carducci MA, de Bono J, Gleave M, Hussain M, Kelly WK, Saad F, Sternberg C, Tagawa ST, et al. New therapies for Castration-Resistant prostate cancer: efficacy and safety. Eur Urol. 2011;60:279\u201390. https:\/\/doi.org\/10.1016\/j.eururo.2011.04.038.","journal-title":"Eur Urol"},{"key":"3607_CR4","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/s41391-020-00310-3","volume":"24","author":"F Saad","year":"2021","unstructured":"Saad F, B\u00f6gemann M, Suzuki K, Shore N. Treatment of nonmetastatic castration-resistant prostate cancer: focus on second-generation androgen receptor inhibitors. Prostate Cancer Prostatic Dis. 2021;24:323\u201334. https:\/\/doi.org\/10.1038\/s41391-020-00310-3.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"3607_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41541-024-01019-3","volume":"9","author":"J Xu","year":"2024","unstructured":"Xu J, Wu Z, Wass L, Larson HJ, Lin L. Mapping global public perspectives on mRNA vaccines and therapeutics. Npj Vaccines. 2024;9:1\u201312. https:\/\/doi.org\/10.1038\/s41541-024-01019-3.","journal-title":"Npj Vaccines"},{"key":"3607_CR6","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/s41568-023-00586-2","volume":"23","author":"C Liu","year":"2023","unstructured":"Liu C, Shi Q, Huang X, Koo S, Kong N, Tao W. mRNA-based cancer therapeutics. Nat Rev Cancer. 2023;23:526\u201343. https:\/\/doi.org\/10.1038\/s41568-023-00586-2.","journal-title":"Nat Rev Cancer"},{"key":"3607_CR7","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/s41585-023-00739-w","volume":"20","author":"I Rastogi","year":"2023","unstructured":"Rastogi I, Muralidhar A, McNeel DG. Vaccines as treatments for prostate cancer. Nat Rev Urol. 2023;20:544\u201359. https:\/\/doi.org\/10.1038\/s41585-023-00739-w.","journal-title":"Nat Rev Urol"},{"key":"3607_CR8","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","volume":"618","author":"LA Rojas","year":"2023","unstructured":"Rojas LA, Sethna Z, Soares KC, Olcese C, Pang N, Patterson E, Lihm J, Ceglia N, Guasp P, Chu A, et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature. 2023;618:144\u201350. https:\/\/doi.org\/10.1038\/s41586-023-06063-y.","journal-title":"Nature"},{"key":"3607_CR9","doi-asserted-by":"publisher","unstructured":"Weber JS, Khattak MA, Carlino MS, Meniawy T, Taylor MH, Ansstas G, Kim KB, McKean M, Sullivan RJ, Faries MB et al. (2024). Individualized neoantigen therapy mRNA-4157 (V940) plus pembrolizumab in resected melanoma: 3-year update from the mRNA-4157-P201 (KEYNOTE-942) trial. JCO 42, LBA9512\u2013LBA9512. https:\/\/doi.org\/10.1200\/JCO.2024.42.17_suppl.LBA9512","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA9512"},{"key":"3607_CR10","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.cell.2020.08.053","volume":"183","author":"PA Ott","year":"2020","unstructured":"Ott PA, Hu-Lieskovan S, Chmielowski B, Govindan R, Naing A, Bhardwaj N, Margolin K, Awad MM, Hellmann MD, Lin JJ, et al. A phase Ib trial of personalized neoantigen therapy plus Anti-PD-1 in patients with advanced melanoma, Non-small cell lung cancer, or bladder Cancer. Cell. 2020;183:347\u2013e36224. https:\/\/doi.org\/10.1016\/j.cell.2020.08.053.","journal-title":"Cell"},{"key":"3607_CR11","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12943-021-01335-5","volume":"20","author":"L Miao","year":"2021","unstructured":"Miao L, Zhang Y, Huang L. mRNA vaccine for cancer immunotherapy. Mol Cancer. 2021;20:41. https:\/\/doi.org\/10.1186\/s12943-021-01335-5.","journal-title":"Mol Cancer"},{"key":"3607_CR12","doi-asserted-by":"publisher","unstructured":"Linch M, Papai Z, Takacs I, Imedio ER, K\u00fchnle M-C, Derhovanessian E, Vogler I, Renken S, Graham P, Sahin U et al. (2021). 421 A first-in-human (FIH) phase I\/IIa clinical trial assessing a ribonucleic acid lipoplex (RNA-LPX) encoding shared tumor antigens for immunotherapy of prostate cancer; preliminary analysis of PRO-MERIT. J Immunother Cancer 9. https:\/\/doi.org\/10.1136\/jitc-2021-SITC2021.421","DOI":"10.1136\/jitc-2021-SITC2021.421"},{"key":"3607_CR13","doi-asserted-by":"publisher","unstructured":"Kallen K-J, Gnad-Vogt U, Scheel B, Rippin G, Stenzl A. A phase i\/iia study of the mRNA based cancer vaccine CV9103 prepared with the RNActive technology results in distinctly longer survival than predicted by the Halabi nomogram which correlates with the induction of antigen-specific immune responses. J Immunother Cancer. 2013;1(P219). https:\/\/doi.org\/10.1186\/2051-1426-1-S1-P219.","DOI":"10.1186\/2051-1426-1-S1-P219"},{"key":"3607_CR14","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/s41571-022-00689-z","volume":"19","author":"A Chow","year":"2022","unstructured":"Chow A, Perica K, Klebanoff CA, Wolchok JD. Clinical implications of T cell exhaustion for cancer immunotherapy. Nat Rev Clin Oncol. 2022;19:775\u201390. https:\/\/doi.org\/10.1038\/s41571-022-00689-z.","journal-title":"Nat Rev Clin Oncol"},{"key":"3607_CR15","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/nri3405","volume":"13","author":"L Chen","year":"2013","unstructured":"Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol. 2013;13:227\u201342. https:\/\/doi.org\/10.1038\/nri3405.","journal-title":"Nat Rev Immunol"},{"key":"3607_CR16","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1038\/s41565-023-01453-9","volume":"18","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Hou X, Du S, Xue Y, Yan J, Kang DD, Zhong Y, Wang C, Deng B, McComb DW, et al. Close the cancer\u2013immunity cycle by integrating lipid nanoparticle\u2013mRNA formulations and dendritic cell therapy. Nat Nanotechnol. 2023;18:1364\u201374. https:\/\/doi.org\/10.1038\/s41565-023-01453-9.","journal-title":"Nat Nanotechnol"},{"key":"3607_CR17","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1158\/0008-5472.CAN-18-2867","volume":"79","author":"OAW Haabeth","year":"2019","unstructured":"Haabeth OAW, Blake TR, McKinlay CJ, Tveita AA, Sallets A, Waymouth RM, Wender PA, Levy R. Local delivery of Ox40l, Cd80, and Cd86 mRNA kindles global anticancer immunity. Cancer Res. 2019;79:1624\u201334. https:\/\/doi.org\/10.1158\/0008-5472.CAN-18-2867.","journal-title":"Cancer Res"},{"key":"3607_CR18","doi-asserted-by":"crossref","unstructured":"Xu Z, Xiao Z-X, Wang J, Qiu H-W, Cao F, Zhang S-Q, Xu Y-D, Lei H-Q, Xia H, He Y-R et al. (2024). Novel mRNA adjuvant ImmunER enhances prostate cancer tumor-associated antigen mRNA therapy via augmenting T cell activity. OncoImmunology.","DOI":"10.1080\/2162402X.2024.2373526"},{"key":"3607_CR19","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13046-021-02215-y","volume":"41","author":"T Flieswasser","year":"2022","unstructured":"Flieswasser T, Van den Eynde A, Van Audenaerde J, De Waele J, Lardon F, Riether C, de Haard H, Smits E, Pauwels P, Jacobs J. The CD70-CD27 axis in oncology: the new kids on the block. J Exp Clin Cancer Res. 2022;41:12. https:\/\/doi.org\/10.1186\/s13046-021-02215-y.","journal-title":"J Exp Clin Cancer Res"},{"key":"3607_CR20","doi-asserted-by":"publisher","first-page":"655","DOI":"10.2217\/imt.15.32","volume":"7","author":"K van de Ven","year":"2015","unstructured":"van de Ven K, Borst J. Targeting the T-cell co-stimulatory CD27\/CD70 pathway in cancer immunotherapy: rationale and potential. Immunotherapy. 2015;7:655\u201367. https:\/\/doi.org\/10.2217\/imt.15.32.","journal-title":"Immunotherapy"},{"key":"3607_CR21","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.immuni.2008.10.009","volume":"29","author":"AM Keller","year":"2008","unstructured":"Keller AM, Schildknecht A, Xiao Y, Van Den Broek M, Borst J. Expression of costimulatory ligand CD70 on Steady-State dendritic cells breaks CD8\u2009+\u2009T cell tolerance and permits effective immunity. Immunity. 2008;29:934\u201346. https:\/\/doi.org\/10.1016\/j.immuni.2008.10.009.","journal-title":"Immunity"},{"key":"3607_CR22","doi-asserted-by":"publisher","first-page":"1023064","DOI":"10.3389\/fimmu.2023.1023064","volume":"14","author":"N Bowakim-Anta","year":"2023","unstructured":"Bowakim-Anta N, Acolty V, Azouz A, Yagita H, Leo O, Goriely S, Oldenhove G, Moser M. Chronic CD27-CD70 costimulation promotes type 1-specific polarization of effector Tregs. Front Immunol. 2023;14:1023064. https:\/\/doi.org\/10.3389\/fimmu.2023.1023064.","journal-title":"Front Immunol"},{"key":"3607_CR23","doi-asserted-by":"publisher","unstructured":"Ning J, Hou X, Hao J, Zhang W, Shi Y, Huang Y, Ruan X, Zheng X, Gao M. METTL3 Inhibition induced by M2 macrophage-derived extracellular vesicles drives anti-PD-1 therapy resistance via M6A-CD70-mediated immune suppression in thyroid cancer. Cell Death Differ. 2023;1\u201315. https:\/\/doi.org\/10.1038\/s41418-023-01217-x.","DOI":"10.1038\/s41418-023-01217-x"},{"key":"3607_CR24","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1038\/s41467-023-37614-6","volume":"14","author":"L Gong","year":"2023","unstructured":"Gong L, Luo J, Zhang Y, Yang Y, Li S, Fang X, Zhang B, Huang J, Chow LK-Y, Chung D, et al. Nasopharyngeal carcinoma cells promote regulatory T cell development and suppressive activity via CD70-CD27 interaction. Nat Commun. 2023;14:1912. https:\/\/doi.org\/10.1038\/s41467-023-37614-6.","journal-title":"Nat Commun"},{"key":"3607_CR25","doi-asserted-by":"publisher","first-page":"e000329","DOI":"10.1136\/jitc-2019-000329","volume":"8","author":"B De Keersmaecker","year":"2020","unstructured":"De Keersmaecker B, Claerhout S, Carrasco J, Bar I, Corthals J, Wilgenhof S, Neyns B, Thielemans K. TriMix and tumor antigen mRNA electroporated dendritic cell vaccination plus ipilimumab: link between T-cell activation and clinical responses in advanced melanoma. J Immunother Cancer. 2020;8:e000329. https:\/\/doi.org\/10.1136\/jitc-2019-000329.","journal-title":"J Immunother Cancer"},{"key":"3607_CR26","doi-asserted-by":"publisher","first-page":"5323","DOI":"10.1158\/1078-0432.CCR-09-0737","volume":"15","author":"MA Cheever","year":"2009","unstructured":"Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, Mellman I, Prindiville SA, Viner JL, Weiner LM, et al. The prioritization of cancer antigens: a National cancer Institute pilot project for the acceleration of translational research. Clin Cancer Res. 2009;15:5323\u201337. https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-0737.","journal-title":"Clin Cancer Res"},{"key":"3607_CR27","doi-asserted-by":"publisher","first-page":"e001649","DOI":"10.1136\/jitc-2020-001649","volume":"9","author":"ZA Lopez-Bujanda","year":"2021","unstructured":"Lopez-Bujanda ZA, Obradovic A, Nirschl TR, Crowley L, Macedo R, Papachristodoulou A, O\u2019Donnell T, Laserson U, Zarif JC, Reshef R, et al. TGM4: an Immunogenic prostate-restricted antigen. J Immunother Cancer. 2021;9:e001649. https:\/\/doi.org\/10.1136\/jitc-2020-001649.","journal-title":"J Immunother Cancer"},{"key":"3607_CR28","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s00262-016-1917-3","volume":"66","author":"PL Stern","year":"2017","unstructured":"Stern PL, Harrop R. 5T4 oncofoetal antigen: an attractive target for immune intervention in cancer. Cancer Immunol Immunother. 2017;66:415\u201326. https:\/\/doi.org\/10.1007\/s00262-016-1917-3.","journal-title":"Cancer Immunol Immunother"},{"key":"3607_CR29","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s00262-018-2266-1","volume":"68","author":"M Besneux","year":"2019","unstructured":"Besneux M, Greenshields-Watson A, Scurr MJ, MacLachlan BJ, Christian A, Davies MM, Hargest R, Phillips S, Godkin A, Gallimore A. The nature of the human T cell response to the cancer antigen 5T4 is determined by the balance of regulatory and inflammatory T cells of the same antigen-specificity: implications for vaccine design. Cancer Immunol Immunother. 2019;68:247\u201356. https:\/\/doi.org\/10.1007\/s00262-018-2266-1.","journal-title":"Cancer Immunol Immunother"},{"key":"3607_CR30","doi-asserted-by":"publisher","first-page":"S543","DOI":"10.1016\/j.annonc.2020.08.2076","volume":"31","author":"M Tuthill","year":"2020","unstructured":"Tuthill M, Cappuccini F, Carter L, Pollock E, Poulton I, Verrill C, Evans T, Gillessen S, Attard G, Protheroe A, et al. 682P results from ADVANCE: A phase I\/II open-label non-randomised safety and efficacy study of the viral vectored ChAdOx1-MVA 5T4 (VTP-800) vaccine in combination with PD-1 checkpoint Blockade in metastatic prostate cancer. Ann Oncol. 2020;31:S543. https:\/\/doi.org\/10.1016\/j.annonc.2020.08.2076.","journal-title":"Ann Oncol"},{"key":"3607_CR31","doi-asserted-by":"publisher","first-page":"e005398","DOI":"10.1136\/jitc-2022-005398","volume":"10","author":"A Vardeu","year":"2022","unstructured":"Vardeu A, Davis C, McDonald I, Stahlberg G, Thapa B, Piotrowska K, Marshall MA, Evans T, Wheeler V, Sebastian S, et al. Intravenous administration of viral vectors expressing prostate cancer antigens enhances the magnitude and functionality of CD8\u2009+\u2009T cell responses. J Immunother Cancer. 2022;10:e005398. https:\/\/doi.org\/10.1136\/jitc-2022-005398.","journal-title":"J Immunother Cancer"},{"key":"3607_CR32","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1158\/1535-7163.MCT-16-0825","volume":"16","author":"J Harper","year":"2017","unstructured":"Harper J, Lloyd C, Dimasi N, Toader D, Marwood R, Lewis L, Bannister D, Jovanovic J, Fleming R, D\u2019Hooge F, et al. Preclinical evaluation of MEDI0641, a Pyrrolobenzodiazepine-Conjugated Antibody\u2013Drug conjugate targeting 5T4. Mol Cancer Ther. 2017;16:1576\u201387. https:\/\/doi.org\/10.1158\/1535-7163.MCT-16-0825.","journal-title":"Mol Cancer Ther"},{"key":"3607_CR33","doi-asserted-by":"publisher","first-page":"2302691","DOI":"10.1002\/adhm.202302691","volume":"13","author":"Y Xu","year":"2024","unstructured":"Xu Y, Hu Y, Xia H, Zhang S, Lei H, Yan B, Xiao ZX, Chen J, Pang J, Zha G-F. Delivery of mRNA vaccine with 1, 2-Diesters-Derived lipids elicits fast liver clearance for safe and effective Cancer immunotherapy. Adv Healthc Mater. 2024;13:2302691. https:\/\/doi.org\/10.1002\/adhm.202302691.","journal-title":"Adv Healthc Mater"},{"key":"3607_CR34","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1007\/s00262-019-02345-5","volume":"68","author":"KM Leick","year":"2019","unstructured":"Leick KM, Pinczewski J, Mauldin IS, Young SJ, Deacon DH, Woods AN, Bosenberg MW, Engelhard VH, Craig L, Slingluff J. Patterns of immune-cell infiltration in murine models of melanoma: roles of antigen and tissue site in creating inflamed tumors. Cancer Immunol Immunotherapy: CII. 2019;68:1121. https:\/\/doi.org\/10.1007\/s00262-019-02345-5.","journal-title":"Cancer Immunol Immunotherapy: CII"},{"key":"3607_CR35","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1038\/s41598-018-37883-y","volume":"9","author":"EJ Lelliott","year":"2019","unstructured":"Lelliott EJ, Cullinane C, Martin CA, Walker R, Ramsbottom KM, Souza-Fonseca-Guimaraes F, Abuhammad S, Michie J, Kirby L, Young RJ, et al. A novel Immunogenic mouse model of melanoma for the preclinical assessment of combination targeted and immune-based therapy. Sci Rep. 2019;9:1225. https:\/\/doi.org\/10.1038\/s41598-018-37883-y.","journal-title":"Sci Rep"},{"key":"3607_CR36","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1200\/JCO.2024.42.3_suppl.356","volume":"42","author":"GP Botta","year":"2024","unstructured":"Botta GP, Kelly RJ, Jin Z, Ma H, Ku GY, Zhao D, Mehta R, Carnevale JC, Sierra G, JIA J, et al. CLDN18.2 chimeric antigen receptor T cell therapy for patients with advanced gastric and pancreatic adenocarcinoma: results of ELIMYN18.2 phase 1b clinical trial. JCO. 2024;42:356\u2013356. https:\/\/doi.org\/10.1200\/JCO.2024.42.3_suppl.356.","journal-title":"JCO"},{"key":"3607_CR37","doi-asserted-by":"publisher","first-page":"8420","DOI":"10.1038\/s41598-019-44874-0","volume":"9","author":"G Zhu","year":"2019","unstructured":"Zhu G, Foletti D, Liu X, Ding S, Melton Witt J, Hasa-Moreno A, Rickert M, Holz C, Aschenbrenner L, Yang AH, et al. Targeting CLDN18.2 by CD3 bispecific and ADC modalities for the treatments of gastric and pancreatic Cancer. Sci Rep. 2019;9:8420. https:\/\/doi.org\/10.1038\/s41598-019-44874-0.","journal-title":"Sci Rep"},{"key":"3607_CR38","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s40425-019-0520-5","volume":"7","author":"A Papachristofilou","year":"2019","unstructured":"Papachristofilou A, Hipp MM, Klinkhardt U, Fr\u00fch M, Sebastian M, Weiss C, Pless M, Cathomas R, Hilbe W, Pall G, et al. Phase Ib evaluation of a self-adjuvanted Protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer. J Immunotherapy cancer. 2019;7:38. https:\/\/doi.org\/10.1186\/s40425-019-0520-5.","journal-title":"J Immunotherapy cancer"},{"key":"3607_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s42003-022-03182-6","volume":"5","author":"F Heckel","year":"2022","unstructured":"Heckel F, Turaj AH, Fisher H, Chan HTC, Marshall MJE, Dadas O, Penfold CA, Inzhelevskaya T, Mockridge CI, Alvarado D, et al. Agonistic CD27 antibody potency is determined by epitope-dependent receptor clustering augmented through Fc-engineering. Commun Biol. 2022;5:1\u201315. https:\/\/doi.org\/10.1038\/s42003-022-03182-6.","journal-title":"Commun Biol"},{"key":"3607_CR40","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1038\/mt.2008.77","volume":"16","author":"A Bonehill","year":"2008","unstructured":"Bonehill A, Tuyaerts S, Van Nuffel AMT, Heirman C, Bos TJ, Fostier K, Neyns B, Thielemans K. Enhancing the T-cell stimulatory capacity of human dendritic cells by co-electroporation with CD40L, CD70 and constitutively active TLR4 encoding mRNA. Mol Ther. 2008;16:1170\u201380. https:\/\/doi.org\/10.1038\/mt.2008.77.","journal-title":"Mol Ther"}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-025-03607-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12951-025-03607-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-025-03607-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T02:39:07Z","timestamp":1752806347000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnanobiotechnology.biomedcentral.com\/articles\/10.1186\/s12951-025-03607-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,18]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3607"],"URL":"https:\/\/doi.org\/10.1186\/s12951-025-03607-4","relation":{},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,18]]},"assertion":[{"value":"28 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Institutional Animal Care and Use Committee, Sun Yat-Sen University approved all the animal procedures (SYSU-IACUC-2024-001444).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"523"}}